34 results about "Ischnocnema bolbodactyla" patented technology

The present invention relates to the use of probiotic microorganism in the manufacture of a composition for the prevention or reduction of gastrointestinal Campylobacter infection in a mammalian animal. It also relates to a method for the prevention or reduction of gastrointestinal Campylobacter infection in a mammalian animal, the method comprising administering to said animal, a probiotic microorganism. The invention also relates to a probiotic microorganism, for use in preventing or reducing gastrointestinal Campylobacter infection in a mammalian animal.

The present inventors succeeded in cloning the CDT genes of C. coli and C. fetus, which were previously unknown, and in determining their sequences. In addition, the inventors also developed specific primers and primers common to the two species by comparing the CDTs of C. jejuni and C. fetus. Furthermore, the inventors demonstrated that these primers were applicable to multiplex PCR that simultaneously allows for the rapid and convenient determination of the presence of Campylobacter CDT and identification of species, and that they can also be used in PCR-RFLP-based typing.

The present inventors succeeded in cloning the CDT genes of C. coli and C. fetus, which were previously unknown, and in determining their sequences. In addition, the inventors also developed specific primers and primers common to the two species by comparing the CDTs of C. jejuni and C. fetus. Furthermore, the inventors demonstrated that these primers were applicable to multiplex PCR that simultaneously allows for the rapid and convenient determination of the presence of Campylobacter CDT and identification of species, and that they can also be used in PCR-RFLP-based typing.

The field of this invention is the development of therapeutic agents having immunogenic efficacy against Campylobacter. The present invention is directed to a method of producing monoclonal antibodies that are highly specific for epitopes of Campylobacter jejuni outer membrane proteins; to specific monoclonal antibodies made by using the epitopes; and to uses thereof. The invention is drawn further to immunogens comprising certain outer membrane proteins or portions thereof from C. jejuni.

The present invention provides a heat-stable and protease-resistant antibacterial activity in excretory-secretory products (ESP) of Trichuris suis. The antibacterial activity is not more than 10,000 MW; is resistant to boiling, trypsin, and pronase E; has a bactericidal mode of action; and is effective against Gram positive and Gram negative bacteria, including Escherichia coli, Campylobacter jejuni, Campylobacter coli, and Staphylococcus aureus. The antibacterial activity is useful in applications for killing or inhibiting the growth of microorganisms, in particular bacteria.

The invention discloses an identification method for campylobacter jejuni infection-associated chicken microRNA. The identification method comprises the following steps of: a first step of collecting chicken meconium, and detecting a positive rate of campylobacter jejuni; a second step of collecting cecum content for counting campylobacter jejuni and cecum tissue samples for RNA extraction; a third step of extracting total RNA of samples, detecting quality, and mixing in a tank; a fourth step of constructing a sequencing sample library; a fifth step of carrying out Solexa sequencing; a sixth step of carrying out subsequent analysis; a seventh step of predicating a target gene of the microRNA; an eighth step of obtaining campylobacter jejuni cfu infection-assocaited chicken microRNAs according to the microRNA and the target gene information thereof. The identification method disclosed by the invention regulates the target gene of the microRNA to indirectly participate in a plurality of immune-associated signal channels, so that important regulation effect is achieved in campylobacter jejuni infection; the microRNAs can be important candidate microRNAs in anti-campylobacter jejuni infection breeding, and foundation is laid up for deeply researching an acting mechanism of the microRNAs in campylobacter jejuni in future, so that theoretical basis and scientific basis are provided for molecular disease-resistant breeding of chicken.

The inventive subject matter relates to an immunogenic composition against Campylobacter jejuni comprising isolated capsule polysaccharide from selected pathogenic Campylobacter jejuni strains. The inventive subject matter also relates to methods of using the polysaccharide compositions in inducing and anti-C. jejuni immune response.

The invention belongs to the field of bacterial drug-resistant molecular detection, and relates to a multiple real-time fluorescent PCR method for identifying the drug-resistant mutation of macrolides and for identifying Campylobacter jejuni. The method is characterized in that an idiocratic primer, MGB probe, and combination of both are designed, not only is the specificity identification performed for the Campylobacter jejuni, but also the mutation of nucleotide of 2074th and 2075th of the 23S rRNA gene of Campylobacter jejuni and that of nucleotide of 170th and 221st of L4 flagellum gene rp1D of ribosome protein can be detected at the same time. The quick detection for drug-resistant mutation points of the various macrolides and the specificity identify for the Campylobacter jejuni are realized, which is first realized in the same reaction system, so that the identification and drug tolerance detection for the Campylobacter jejuni in clinical trials is greatly reduced, and as a result, a novel method is provided for Campylobacter jejuni drug-resistant monitoring and medicines for clinical trials infection treatment.

The invention integrates mispairing amplification mutation analysis PCR (MAMA-PCR) and a multiple PCR technique, and provides a method for rapidly detecting quinolone antibiotics campylobacter jejuni caused by point mutation of nucleotide and a kit. The kit comprises a primer composition with the nucleotide sequence shown by SEQ ID No.1-5 and SEQ ID No.7 in the sequence list and a quality control group primer composition with the nucleotide sequence shown by SEQ ID No.1-6 in the sequence list. By adopting the detection method and the kit, campylobacter jejuni of the quinolone antibiotics can be rapidly identified from suspected bacteria, and complex procedures of the traditional detection method using strain identification and drug sensitive test as the representative are simplified. The method and the kit have favorable specificity and sensitivity, and are very suitable for rapidly detecting suspected bacteria at the frontline to provide accurate medicine instructions.

The invention discloses lactobacillus plantarum. The Lactobacillus plantarum can antagonize campylobacter jejuni and inhibit expression of a flaA gene of the campylobacter jejuni, has the good acid resistance and bile salt resistance, can inhibit growth of the campylobacter jejuni in vitro and has the good adhesive capacity on the intestinal epithelial cells. A fermentation supernatant of the lactobacillus plantarum enables the expression amount of the flaA gene of the campylobacter jejuni to be reduced by 8.2 times compared with a control group in vitro, and synthesis of campylobacter jejuni flagella is effectively inhibited; the lactobacillus plantarum enables the expression amount of the flaA gene of the campylobacter jejuni to be reduced by 1.7 times compared with a control group in a cell model. The lactobacillus plantarum can be used for preparing medicine for preventing and treating diseases caused by the campylobacter jejuni and participate in preparing fermentation milk products and the like and has the wide application prospect.

The invention discloses Lactobacillus reuteri, which can antagonize Campylobacter jejuni and inhibit its flaA gene expression, has better acid and bile salt tolerance, can inhibit in vitro the growth of Campylobacter jejuni, and has better ability to adhere intestinal epithelial cells. Ferment supernate of Lactobacillus reuteri has the expression of flaA gene of Campylobacter jejuni down-regulated in vitro by 11.1 times when compared to a control, and the synthesis of flagella of Campylobacter jejuni can be effectively inhibited; the ferment supernate of Lactobacillus reuteri has the expression of the flaA gene of Campylobacter jejuni down-regulated in a cell model by 1.4 times when compared to a control. The Lactobacillus reuteri is applicable to the preparation and drugs for preventing and treating diseases caused by Campylobacter jejuni, for the preparation of fermented milk and the like, and has a promising application prospect.